Dried blood spot (DBS) technology is increasingly integrated into drug research, from therapeutic drug monitoring to pharmacokinetic (PK) studies in clinical trials. Unlike conventional venous blood draws, DBS requires only 50 – 80 microliters of blood, simplifying collection and storage. For researchers and pharmaceutical developers, DBS enables more flexible study designs, reduces patient burden, and provides opportunities to collect high-quality data under real-world conditions.
Incorporating DBS into drug studies begins during the planning phase. Researchers must confirm that the target analytes — whether small-molecule drugs, metabolites, or larger biomolecules — can be reliably quantified from dried blood. Since each DBS spot contains only 50 – 80 µL of blood, sampling schedules should be tailored accordingly. This limitation is often offset by the ability to collect more frequent time-point samples, particularly useful in pediatric or outpatient settings. By designing studies around DBS’s strengths, researchers can achieve richer pharmacokinetic profiles while minimizing participant discomfort.
Consistency in sample collection is essential. All study staff or participants should be trained in the proper DBS technique, including finger selection, lancet use, sample application, drying, and storage. Clear standard operating procedures (SOPs) reduce variability and improve sample quality. Many studies provide participants with DBS kits that include lancets, cards, desiccants, and instructions, ensuring uniformity across trial sites. RDA Spot kits, for example, are designed to simplify training and standardization in multicenter trials.
Maintaining high sample quality requires attention to drying and storage conditions. Each blood spot should be fully saturated and dried in a clean environment before sealing with a desiccant. Humidity and heat can degrade sensitive analytes, so storage protocols must be enforced rigorously. Researchers should also account for the impact of hematocrit levels, which can affect how blood spreads on filter paper and influence quantification. Method validation should include an assessment of how varying hematocrit ranges impact assay performance.
Successful use of DBS in drug studies depends on robust bioanalytical methods. Laboratories must validate extraction and detection techniques — typically LC-MS/MS — according to regulatory standards such as FDA and EMA bioanalytical guidelines. Validation includes confirming accuracy, precision, stability, and reproducibility of assays using DBS samples. Addressing matrix effects and assessing analyte recovery are also critical steps in ensuring reliable results. With proper validation, DBS assays can match the rigor of plasma-based methods.
DBS has been applied in numerous therapeutic areas. In oncology, it supports therapeutic drug monitoring for transplant conditioning drugs like busulfan. In infectious disease research, DBS facilitates antiretroviral pharmacokinetics and adherence monitoring. Pediatric studies also benefit, as DBS enables frequent sampling with minimal blood volume, an approach that would be impractical using venous blood. The reduced logistical burden of shipping dried samples further supports global, multicenter trials.
Dried blood spot cards offer unique advantages for drug studies by simplifying collection, improving patient compliance, and enabling broader research participation. When paired with validated laboratory methods and standardized protocols, DBS can deliver data of comparable quality to traditional plasma sampling. With RDA Spot’s specialized DBS kits, researchers can confidently integrate this microsampling technique into clinical and pharmacological studies, unlocking new efficiencies in drug development and therapeutic monitoring.